StreetInsider.com News Articles

Azitra announces 1-for-10 reverse stock split effective Oct. 26

Fri, 16 Oct 2026 08:00:27 -0400

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company, announced a 1-for-10 reverse stock split of its common stock, effective at 12:01 a.m. Eastern Time on October 26, 2026.

The company's board of directors approved the final split ratio on October 14, 2026. Stockholders had granted the board authority to effect a reverse stock split at a ratio between 1-for-2 and 1-for-30 at the annual meeting held on June 15, 2026.

Azitra's common stock will continue to trade on the NYSE American under the ticker symbol "AZTR" and will begin trading on a split-adjusted basis when the market opens on October 26,

Azitra, Inc. Announces Reverse Stock Split

Fri, 16 Oct 2026 08:00:00 -0400

Common Stock Will Begin Trading on a Split-Adjusted Basis on October 26, 2026

BRANFORD, Conn., Oct. 16, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for

Azitra, Inc. Announces Reverse Stock Split

Fri, 16 Oct 2026 08:00:00 -0400

Common Stock Will Begin Trading on a Split-Adjusted Basis on October 26, 2026

Form 8-K Azitra, Inc. For: Oct 01

Thu, 01 Oct 2026 08:11:00 -0400

si-local-file:///var/storage/secattach/20261001/27131957.html

Azitra advances ATR-04 trial to second cohort after safety review

Thu, 01 Oct 2026 08:01:54 -0400

Azitra, Inc. (NYSE American: AZTR) announced Oct. 1 that its Phase 1/2 clinical trial evaluating ATR04-484 has advanced to Cohort 2 after a safety review committee cleared the study to proceed based on data from the first cohort.

The multicenter, randomized, double-blind, vehicle-controlled trial (NCT06830863) is evaluating the safety, tolerability, bioavailability, pharmacodynamics, and preliminary efficacy of topical ATR-04 for the treatment of EGFR inhibitor (EGFRi)-associated skin rash in adult patients. Seven patients were enrolled in Cohort 1, with six included in the safety review. Each received a single 4g application to the face, chest, and back, followed by a 7-day observation

Azitra, Inc. Advances ATR-04 Phase 1/2 Clinical Trial to Cohort 2 Following Safety Review Committee Clearance

Thu, 01 Oct 2026 08:00:00 -0400

BRANFORD, Conn., Oct. 1, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the completion of Cohort 1 in its Phase 1/2 clinical trial evaluating ATR04-484 as a potential treatment for EGFR inhibitor (EGFRi)-associated skin rash. Following its review of available safety data from patients enrolled in Cohort 1, the study's safety review committee recommended

Azitra, Inc. Advances ATR-04 Phase 1/2 Clinical Trial to Cohort 2 Following Safety Review Committee Clearance

Thu, 01 Oct 2026 08:00:00 -0400

Form 8-K Azitra, Inc. For: Sep 28

Mon, 28 Sep 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260928/27115246.html

Form 424B5 Azitra, Inc.

Mon, 28 Sep 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260928/27115197.html

Form 8-K Azitra, Inc. For: Sep 08

Tue, 08 Sep 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260908/27033657.html

Azitra, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 08 Sep 2026 08:00:00 -0400

BRANFORD, Conn., Sept. 8, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today announced that Travis Whitfill Ph.D., MPH, Azitra's Co-founder and Chief Operating Officer, will deliver a virtual presentation at the H.C. Wainwright 28th Annual Global Investment Conference, to be held from September 14-16, 2026, in New York City.

Azitra, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 08 Sep 2026 08:00:00 -0400

Form 8-K Azitra, Inc. For: Aug 21

Fri, 21 Aug 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260821/26958638.html

Form 8-K Azitra, Inc. For: Aug 21

Fri, 21 Aug 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260821/26958638.html

Azitra regains NYSE American listing compliance

Fri, 21 Aug 2026 08:00:58 -0400

Azitra, Inc. (NYSE American: AZTR) announced it received written notification from NYSE American LLC confirming the company has regained compliance with all continued listing standards set forth in Part 10 of the NYSE American Company Guide.

In a letter dated Aug. 19, 2026, NYSE Regulation informed Azitra that the company resolved previously disclosed listing deficiencies under Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide. As a result, the "below compliance" indicator will no longer be disseminated, and Azitra will be removed from NYSE American's list of noncompliant issuers.

The company will remain subject to NYSE Regulation's continued listing monitoring procedures.

Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards

Fri, 21 Aug 2026 08:00:00 -0400

BRANFORD, Conn., Aug. 21, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today announced that it has received written notification from NYSE American LLC ("NYSE American") confirming that the Company has regained compliance with all of the NYSE American continued listing standards set forth in Part 10 of the NYSE American Company Guide.

Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards

Fri, 21 Aug 2026 08:00:00 -0400

Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards

Fri, 21 Aug 2026 08:00:00 -0400

Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards

Fri, 21 Aug 2026 08:00:00 -0400

Form SCHEDULE 13G Azitra, Inc. Filed by: Nantahala Capital Management, LLC

Fri, 14 Aug 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260814/26931989.html

Form SCHEDULE 13G Azitra, Inc. Filed by: Nantahala Capital Management, LLC

Fri, 14 Aug 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260814/26931989.html

Form SCHEDULE 13G Azitra, Inc. Filed by: Nantahala Capital Partners Limited Partnership

Fri, 14 Aug 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260814/26931847.html

Form SCHEDULE 13G Azitra, Inc. Filed by: Nantahala Capital Partners Limited Partnership

Fri, 14 Aug 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260814/26931847.html

Azitra, Inc. (AZTR) Tops Q2 EPS by 54c

Thu, 13 Aug 2026 09:32:04 -0400

Azitra, Inc. (NYSE: AZTR) reported Q2 EPS of ($0.17), $0.54 better than the analyst estimate of ($0.71).

For earnings history and earnings-related data on Azitra, Inc. (AZTR) click here.

Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates

Wed, 12 Aug 2026 17:00:00 -0400

BRANFORD, Conn., Aug. 12, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today reported financial results for the quarter ended June 30, 2026, and provided a business update.